Aurinia Pharmaceuticals AUPH Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's other commercial liabilities?
- Aurinia Pharmaceuticals (AUPH) reported other commercial liabilities of $58.2M in Q1 2026.
- How has Aurinia Pharmaceuticals's other commercial liabilities changed year-over-year?
- Aurinia Pharmaceuticals's other commercial liabilities increased by 37.4% year-over-year, from $42.35M to $58.2M.
- What is the long-term trend for Aurinia Pharmaceuticals's other commercial liabilities?
- Over 2 years (2023 to 2025), Aurinia Pharmaceuticals's other commercial liabilities has grown at a 15.4% compound annual growth rate (CAGR), from $50.06M to $66.62M.